Compare JCI & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JCI | BSX |
|---|---|---|
| Founded | 1885 | 1979 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.0B | 137.8B |
| IPO Year | 2007 | 2010 |
| Metric | JCI | BSX |
|---|---|---|
| Price | $135.47 | $70.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 20 |
| Target Price | ★ $132.54 | $109.15 |
| AVG Volume (30 Days) | 3.7M | ★ 12.8M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | ★ 99.60 | 55.20 |
| EPS | 0.85 | ★ 1.94 |
| Revenue | ★ $9,902,000,000.00 | $9,076,000,000.00 |
| Revenue This Year | $7.66 | $12.04 |
| Revenue Next Year | $6.44 | $10.48 |
| P/E Ratio | $155.48 | ★ $36.74 |
| Revenue Growth | N/A | ★ 12.49 |
| 52 Week Low | $68.03 | $70.75 |
| 52 Week High | $146.49 | $109.50 |
| Indicator | JCI | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 31.39 |
| Support Level | $111.18 | N/A |
| Resistance Level | $146.49 | $76.77 |
| Average True Range (ATR) | 3.22 | 1.73 |
| MACD | -1.98 | 0.24 |
| Stochastic Oscillator | 29.99 | 8.23 |
Following Johnson Controls' divestiture of its residential and light commercial HVAC businesses to Bosch in 2025, nearly all of its revenue comes from commercial HVAC (60%) and fire and security products and services (40%). A 2016 merger joined Johnson Controls' HVAC and Tyco's fire and security businesses with the premise that there is synergy in offering a broader variety of automation products and solutions to commercial buildings. We estimate Johnson Controls' pro forma revenue mix will be one-third products, one-third installation, and one-third services.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.